Recently there has become available a number of new semisynthetic cephalosporin antibiotics for intramuscular and intravenous use. Since to date no single preparation is more effective than another, an agent would be a useful addition to hospital formularies only if intravenous injections of the drug were better tolerated.
Phlebitis is a common and troublesome side effect of intravenous cephalosporin therapy. There have been conflicting reports as to whether the use of a newer cephalosporin antibiotic preparation, cephapirin, results in a lower incidence of phlebitis (1-5). To determine which situation prevailed in our hospital, the incidence and severity of phlebitis was determined and compared to cephalothin in a singleblind fashion.
Patients receiving cephapirin or cephalothin were identified by the pharmacy. These patients, male and female adults, were then examined by one or both authors. The drug preparation that the patient was receiving was not known to the authors until after the patient was taken off therapy.
The dose of the antimicrobial was not controlled since we wished to study the drugs as they would normally be used in the hospital by ward physicians. The dose of cephalothin ranged from 500 mg every 6 h to 2 g every 4 h, but most patients received 1 g every 6 to 8 h. The dose of cephapirin ranged from 667 mg every 12 h to 3.33 g every 6 h, but most received 1 g every 8 h. In over 90% of the cases, a polyethylene long-dwell catheter was used and the catheter was placed in an arm or hand vein. These catheters stayed in place from 24 to 216 h; however, the great preponderance had the catheter in the same site less than 4 days (Table 1 and 2).
Antibiotics were administered within a halfhour and the only medications traversing the same infusion site were gentamicin, carbenicillin, and potassium chloride (the latter was always less than 20 meq and given over long periods of time). Seventy-seven patients received cephalothin and 43 patients received cephapirin (Table 1 and 2). There was no significant difference in the incidence of reactions (P > 0.5). Both groups of patients had a high overall rate of phlebitis associated with cephalosporin use, 49% for cephapirin, and 55% for cephalothin.
Cephalothin therapy did, however, result in a greater severity of phlebitis but this was not statistically significant (P > 0.12). Of those receiving cephalothin, 23% had 2+ or 3+ reactions as opposed to 12% receiving cephapirin. The likelihood of reactions to both drugs increased with increasing duration ofcatheterization.
The number of infusions lasting 2 days or less was similar for both groups. Ten of 51 patients treated with cephalothin for 2 days or less had 2+ or 3+ phlebitis, whereas only l of 33 patients treated with cephapirin for 2 days or less had phlebitis with this degree of severity. This is a highly significant difference (P < 0.005).
Cephapirin sodium is a cephalosporin for parenteral use that has a spectrum and an activity equivalent to those for cephalothin (1). The dosage, blood levels, minimal inhibitory concentration and excretion patterns are also similar (5). However, there are conflicting data on the incidence of phlebitis with cephapirin (Table 3) . Quintiliani et al. (5) gave cephapirin intravenously to 22 patients with a wide spectrum of infectious diseases and found no phlebitis. In a single-blinded study of 10 healthy subjects, cephalothin caused phlebitis more frequently and more severely than did cephapirin (4). Inagaki and Bodey (3) reported that while the overall incidence of phlebitis was similar for both drugs, severe phlebitis occurred twice as often in the cephalothin-treated group.
On the other hand, a double-blind study of 20 patients reported no difference in either the incidence or the degree ofphlebitis with the two cephalosporins (5) .
Our study suggests that the overall incidence and severity of phlebitis is similar in both groups; however, cephapirin gave significantly less severe reactions during the first 48 h of infusion.
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